105807-83-8

Basic information

• Product Name: 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• Synonyms: 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;7-amino-2,2-dimethyl-2H-1,4-benzoxazin-3(4H)-one;7-Amino-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H);7-Amino-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one
• CAS NO: 105807-83-8
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.22
• Mol File: 105807-83-8.mol

Chemical Properties

• Boiling Point: 396.859°C at 760 mmHg
• Flash Point: 193.813°C
• Appearance: /
• Density: 1.197g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(105807-83-8)
• EPA Substance Registry System: 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(105807-83-8)

Safety Data

• Hazardous Substances Data: 105807-83-8(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
7-Amino-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-ONE is used as a research compound for studying its chemical properties and potential applications in various fields. Its unique structure allows researchers to explore its reactivity, polarity, and other characteristics that may be beneficial in the development of new materials or processes.
Used in Industrial Applications:
7-Amino-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-ONE is used as a chemical intermediate in the synthesis of other compounds or materials. Its specific structure and properties may be harnessed in the production of specialty chemicals, pharmaceuticals, or other advanced materials, depending on its reactivity and compatibility with other substances.
Note: Since the provided materials do not specify particular applications or industries for 7-Amino-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-ONE, the uses listed above are general and based on the information available. Further research and data would be required to identify specific applications and industries where 7-AMINO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is utilized.

InChI:InChI=1/C10H12N2O2/c1-10(2)9(13)12-7-5-6(11)3-4-8(7)14-10/h3-5H,11H2,1-2H3,(H,12,13)

Upstream product

• 85160-83-4 2,2-dimethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 121-88-0 5-Nitro-2-aminophenol 

Downstream Products

• 130137-49-4 1-(4-Bromo-phenyl)-3-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-thiourea 
• 945966-46-1 N-(4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)methanesulfonamide 
• 945969-61-9 7-amino-4-(4-chloro-3-methylphenyl)-2,2-dimethyl-2H-1,4-benzoxazin-3(4H)-one 
• 130137-60-9 1-(4-Bromo-phenyl)-3-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 130137-59-6 1-(4-Chloro-phenyl)-3-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 130137-58-5 1-(2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-3-phenyl-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 130137-48-3 1-(4-Chloro-phenyl)-3-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-thiourea 
• 130137-47-2 1-(2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-3-phenyl-thiourea 
• 105202-22-0 7-Amino-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one; hydrochloride 

Relevant articles and documents

Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer

Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration-resistant prostate cancer. A series of 2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.

Benzomorpholone derivative as well as preparation method and application of benzomorpholone derivative

The invention belongs to the field of chemical medicines and particularly relates to a benzomorpholone derivative as well as a preparation method and application of the benzomorpholone derivative. The invention provides a benzomorpholone derivative with a structure as shown in the formula I and also provides a preparation method and application of the benzomorpholone derivative. The benzomorpholone derivative provided by the invention is novel in structure, has a good effect on selectively inhibiting BET targets, produces cytotoxicity for various tumor cells to different extents and is a novel BET small-molecule inhibitor. The compound disclosed by the invention has the potential to develop antitumor drugs.

Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities

The bromodomain and extra-terminal proteins (BETs), in particular BRD4, has been reported to play important roles in cancer, inflammation, obesity, cardiovascular disease, and neurological disorders. In this paper, a series of benzomorpholinone derivatives were synthesized and biologically evaluated as BETs inhibitors. Detailed structure–activity relationship studies led to the discovery of several new potent compounds, of which 15h and 15i displayed IC 50 values of 2.8 and 4.5 μ M against BRD4 (D1), respectively, and showed good anti-proliferation activities against four hematologic malignancies cell lines at low-micromolar concentrations, including MV4-11, OCI-LY10, Pfeifer, and Su-DHL-6 cells. This chemotype could be further optimized with respect to its potency and drug-like properties in the future.

METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND

The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine

BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS

The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group

Synthesis and Anthelmintic Activity of Some New 6- and 7-Isothiocyanato-2H-1,4-benzoxa(thia)zin-3(4H)-ones and Benzoxa(thia)zin-3(4H)-thiones

A series of 6- and 7-isothiocyanato-2H-1,4-benzoxa(thia)zin-3(4H)-ones (8a-n, 9a-c, 12a-i and 12l) and thiones (10a-h and 11a-c) has been prepared for anthelmintic testing.Some of these compounds possess a significant degree of activity against hookworm i